We demonstrate editing of post-mitotic neurons in the adult mouse brain following injection of Cas9 ribonucleoprotein (RNP) complexes in the hippocampus, striatum and cortex. Engineered variants of Cas9 with multiple SV40 nuclear localization sequences enabled a tenfold increase in the efficiency of neuronal editing in vivo. These advances indicate the potential of genome editing in the brain to correct or inactivate the underlying genetic causes of neurological diseases. Fig. 1a) . NexGen sequence analysis (NGS) of the locus confirmed Cas9 RNP-induced insertion/deletion (indel) mutations (Supplementary Fig. 2b ). PCR analysis of genomic DNA from the edited tdTomato stop cassette revealed a DNA laddering pattern, and FACS sorting followed by genomic DNA PCR analysis showed tdTomato reporter activation required a specific double deletion (Supplementary Fig. 2c ). Sanger sequencing of the other edited alleles identified additional edits that did not activate tdTomato ( Supplementary Fig. 2d,e) . Quantification of the double-deletion PCR band correlated closely with the percentage of tdTomato + cells measured by flow cytometry. Therefore, although the number of tdTomato + cells under-reports RNP total editing, the tdTomato mouse can be used to visually detect genome editing by Cas9 RNPs, and should enable visualization of edited cells in vivo.
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Cas9 RNP has no innate cell-penetrating activity, and its direct delivery into cells requires chemical conjugation of polyarginine peptides, a strategy prone to inefficiency and heterogeneity 18 , or mixing with lipid carrier molecules 5, 16 , which are immunogenic, inflammatory and toxic 19, 20 . In previous work, arrays of Simian vacuolating virus 40 nuclear localization sequence (SV40-NLS) enhanced the innate cell-penetrating capabilities of zinc finger nucleases 21 . The Cas9 protein we used for cell-based experiments contained two SV40-NLSs on the C terminus, Cas9-2×NLS. However, we found that RNPs generated using this protein were not cell-penetrating and did not result in genome editing when added directly to the media of cultured cells (even in the absence of serum). To test potential cell-penetrating properties, we designed Cas9 proteins with increasing numbers of N-terminal SV40-NLS arrays that we call 0×, 1×, 2×, 4× and 7×NLS-Cas9-2×NLS (Supplementary Table 1 ). These were made with and without superfolder (sf)GFP 22 fused on the C terminus (Fig. 1c) . We delivered RNPs to the media of tdTomato NPC cultures. TdTomato reporter activation increased markedly as the number of N-terminal NLS sequences on Cas9 was increased from none to four copies and decreased for 7×NLS-Cas9-2×NLS (Fig. 1d) . TdTomato was not detected with a non-targeting sgRNA. PCR analysis of tdTomato locus confirmed the expected laddering pattern, indicating deletion edits and, as anticipated, showed higher total deletion efficiency than reported by the percentage of dTomato + cells (Fig. 1e) .
We bypassed the requirement for protein-based cell penetration by mixing RNPs with Lipofectamine2000 to trigger RNP delivery into the cytoplasm by cell membrane fusion in HEK293 cells with a GFP reporter 5 or by using a NaCl hypertonic protein transduction protocol in tdTomato NPCs 23 . We observed gene editing in both cell types; editing activity was not significantly different between RNP variants at all RNP doses delivered (HEK293 P = 0.9032 and tdTomato NPCs P = 0.8685, Supplementary Fig. 3a,b) . Similar findings were obtained in terminally differentiated neurons, where direct delivery B r i e f c o m m u n i c at i o n s of 4×NLS-Cas9-2×NLS but not 0×NLS-Cas9-2×NLS RNPs triggered genome editing in mature neurons (Supplementary Fig. 3c ), but when RNPs were mixed with Lipofectamine2000, both triggered genome editing (Supplementary Fig. 3d ). Together these results support our hypothesis that 4×NLS-Cas9-2×NLS RNPs have enhanced cell-penetration capabilities. (pmol):  100  30  10   0  3  100  30  10   70%  57%  42%  11%   4×NLS-noGFP  7×NLS  4×NLS  2×NLS  1×NLS pmol RNP 100 10 1 
B r i e f c o m m u n i c at i o n s
We next tested the activity of the 4×NLS-Cas9-2×NLS and 0×NLS-Cas9-2×NLS RNPs in adult tdTomato mouse brains using an intracranial RNP injection system. To test RNP activity in diverse neuronal subtypes, we performed stereotaxic injections (4 pmol per 0.5 µL) in four brain regions: hippocampus, dorsal striatum, primary somatosensory cortex (S1) and primary visual cortex (V1) (Fig. 2a) . We analyzed brains 12-14 d after injection to allow time for tdTomato protein to be expressed and to accumulate in genome-edited cells.
In vivo genome editing was observed for both the 4×NLS-Cas9-2×NLS and 0×NLS-Cas9-2×NLS RNPs that targeted tdTomato, but not for RNPs loaded with non-targeting sgRNA, showing RNP specificity. Similar to in vitro results, the 4×NLS-Cas9-2×NLS RNP was tenfold more efficient at editing cells in the brain compared to the 0×NLS-Cas9-2×NLS RNP in all four brain regions tested (Fig. 2b) .
We next performed dual-color immunofluorescence to identify the cell types that 4×NLS-Cas9-2×NLS RNP edits in vivo. In the cortex, tdTomato + cells co-localized with NeuN (post-mitotic neuronal marker). In the hippocampus, tdTomato + cells co-localized with CTIP2 (also known as BCL11a), a transcription factor present in CA1 hippocampus and striatal post-mitotic neurons. Interestingly, in the hippocampus tdTomato + cells did not co-localize with GFAP, an astrocyte marker protein. In the striatum, tdTomato + cells co-localized with CTIP2 and DARPP-32 (cAMP-regulated neuronal phosphoprotein), a well-documented marker of GABAergic striatal medium spiny neurons. As in the hippocampus, genome-editing was not detected in astrocytes as there was no tdTomato + co-localization with GFAP or S100β, (a protein highly expressed in striatal astrocytes) (Fig. 2c) . Therefore, our cellular analysis showed 4×NLS-Cas9-2×NLS-RNPmediated editing of diverse neuronal subtypes and not astrocytes.
To investigate whether a higher dose of 4×NLS-Cas9-2×NLS RNPs would increase the number or volume of genome-edited cells, we performed a 4-, 15-and 30-pmol RNP per 0.5 µl intrastriatal injection dose course. We observed significantly more tdTomato + cells with increasing RNP dose, 4 pmol (588 ± 90 cells), 15 pmol (1,339 ± 331 cells), 30 pmol (2,675 ± 613 cells), 4 pmol vs. 30 pmol (P = 0.0188) (Fig. 2e,f) . We noted the highest RNP dose (30 pmol) had a threefold larger volume of tdTomato + tissue compared to the lowest RNP dose (4 pmol), ~1.5 mm 3 vs. ~1 mm 3 ( Supplementary Fig. 4 ). Since the same injection volume was used for each RNP dose, this result hints at a volume-independent mechanism of RNP spreading through the striatum interstitial space. We also observed increased density of tdTomato + -edited cells in the 30-pmol Cas9 RNP ( Fig. 2e and Supplementary Fig. 4c) . Notably, the efficiency of 4×NLS-Cas9-2×NLS-RNP-mediated genome editing was ~100 tdTomato + cells per pmol of RNP delivered and was not significantly different across the three RNP doses (P = 0.213) (Fig. 2g) . This suggests that calculating the amount of RNP needed to edit a given number of neurons could be possible (Supplementary Fig. 5 ).
To assess whether there is an innate immune response to Cas9 RNP injected into the dorsal striatum, we analyzed activation of microglia, CNS resident immune cells, by IBA-1 immunostaining and relative transcript expression of a panel of immune marker genes by qPCR (Supplementary Table 2 ). We did not observe significant IBA-1 intensity differences or morphological differences among uninjected, sham-injected and RNP-injected brains, and qPCR of immune-related transcripts suggests an undetectable to mild microglia-mediated innate immune response following Cas9 RNP injection (Supplementary Fig. 6 ). The increased TNF-alpha transcript levels at 12 d after injection could reflect an adaptive response to RNP delivery that reduces synaptic strength of the corticostriatal pathway for neuroprotection 24 and not an innate immune response. Future studies will explore this possibility.
Overall, our findings demonstrate efficient Cas9-RNP-mediated genome editing of neural progenitor cells in vitro and neurons in distinct brain regions in vivo. Although the mechanism of 4×NLS-Cas9-2×NLS RNP in vivo neurotropism is not yet understood, it can be exploited for neuron-specific targeting. Therefore, this technology has the potential to be applied to treat genetic neurological diseases that are manifested in distinct populations of neurons. The evidence that functional Cas9 RNPs can be effectively, precisely and safely delivered to neurons in the brains of adult animals in a non-genetically encoded manner has implications for future therapeutic use of Cas9-RNP complexes to treat neurological disease and for tissue-specific editing in general.
METhodS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. 
oNLINE METhodS
Neural progenitor cell (NPCs) line creation. NPCs were isolated from cortices from embryonic day 13.5 Ai9-tdTomato homozygous mouse embryos 17 . Cells were cultured as neurospheres in NPC medium: DMEM/F12 with glutamine, Na-Pyruvate, 10 mM HEPES, non-essential amino acid, penicillin and streptomycin (100×), 2-mercaptoethanol (1,000×), B-27 without vitamin A, N2 supplement, bFGF and EGF, both 20 ng/ml as final concentration. NPCs were passaged using MACS Neural Dissociation Kit (Papain) cat# 130-092-628 following manufacturer's protocol. bFGF and EGF were refreshed every other day and passaged every 6 d. The NPC line was authenticated by immunocytochemistry marker protein staining. They were tested for mycoplasma using Hoechst stain with visual analysis and were negative.
Cas9 RNP direct delivery. Direct delivery RNP in NPC experiments was added to media and incubated with cells for 24 h, then cells were washed 2× with 200 U/ml heparin in DMEM media and allowed to grow for 24 additional hours.
HEK293T-EGFP-PEST cell line creation. The d2EGFP reporter construct was created in a modified lentivirus backbone with EF1-a promoter driving the gene of interest and a second PGK promoter driving production of a gene that confers resistance to hygromycin. The EGFP is destabilized by fusion to residues 422-461 of mouse ornithine decarboxylase, giving an in vivo half-life of ~2 h. Transduced 293T cells were selected with hygromycin (250 µg/ml). d2EGFP clones were isolated by sorting single cells into 96-well plates and characterized by intensity of d2EGFP. Lentivirus was produced by PEI (Polysciences Inc., 24765) transfection of 293T cells with gene delivery vector co-transfected with packaging vectors pspax2 and pMD2.G essentially as described 25 . The parental HEK293T cell line was obtained from UC Berkeley Scientific Facilities and authenticated using short tandem repeat analysis. They were tested for mycoplasma using Hoechst stain with visual analysis and were negative. HEK 293T EGFP disruption assay. GFP disruption assays were based on those previously described 26 . HEK-293T-d2EGFP cells were used in these experiments because they are efficiently transfected with Cas9 RNP mixed with lipofectamine2000 and, therefore, useful for this experiment which analyzes the activity of our 0×NLS-and 4×NLS-Cas9-2×NLS RNPs after cell penetration. Briefly, HEK293T-d2EGFP cells were cultured in 10-cm dishes using Dulbecco's Modification of Eagle's Medium (DMEM) with 4.5g/L glucose l-glutamine and sodium pyruvate (Corning Cellgro) plus 10% FBS, 1× MEM Non-Essential Amino Acids Solution (Gibco), and penicillin and streptomycin (Gibco). One day before transfection, ~3 × 10 4 cells were plated into each well of a 96-well plate with the DMEM medium plus hygromycin and allowed to settle. The next day Cas9 RNP was complexed with Lipofectamine 2000 (Life Technologies) at 0.005-50 pmol RNP+ 1 µl Lipofectamine in 20 µl OMEM media and added to the cells. Cells were analyzed for EGFP expression at 48 h after transfection using a BD LSR Fortessa high-throughput sequencer.
NaCl hypertonic protein transduction. RNPs were added to NaCl hypertonic protein transduction solution, CRISPR/Cas9 Transduction Media: Opti-MEM media (Life Technologies) supplemented with 542 mM NaCl, 333 mM GABA, 1.673 N 2 , 1.673 B27 minus vitamin A, 1.673 non-essential amino acids, 3.3 mM glutamine, 167 ng/ml bFGF2, and 84 ng/ml EGF 23 . This mixture was added to NPCs that were plated 1 d before at 9×10 4 cells per well of 96-well plate. The CRISPR/Cas9 Transduction Media + Cas9 RNPs were removed after 1 h and replaced with growth media. Editing efficiency was assessed by FACS and genomic DNA PCR analysis.
Primary neuron culture. E18.5 cortical neurons were dissociated with MACS Neural Dissociation Kit (Papain) cat# 130-092-628 following manufacturer's protocol. Cells were seeded in NBActive media (Brainbits) at 1,500 cells/mm 2 on poly-ornithine-, fibronectin-, laminin-coated, imaging-quality, 96-well plates (Greiner Bio One). On day in vitro (DIV) 4, 1/3 media was changed, on DIV 8, 1/3 media was changed, and RNP or RNP + Lipofectamine2000 added to cells. Per well, 0.5 µl Lipofectamine 2000 + 5 µl OMEM was incubated for 10 min at room temp. To this, 10 pmol RNP + 5 µl OMEM was added and incubated for 10 min at room temp, then added to cells. The RNP or RNP + LNP was incubated for 16 h, at which point media was removed and pre-equilibrated, 50% conditioned media added to cells.
Cas9 purification. The recombinant Streptococcus pyogenes Cas9 used in this study carries two C-terminal SV40 nuclear localization sequences. The protein was expressed with an N-terminal hexahistidine tag and maltose binding protein in Escherichia coli Rosetta 2 cells (EMD Millipore, Billerica, MA) from plasmids based on pMJ915 (Addgene plasmid # 69090) 14 . N-terminal nuclear localization sequence peptide arrays and sfGFP modifications were cloned into the plasmid using Gibson DNA assembly technique (Supplementary Table 1) . The His tag and maltose binding protein were cleaved by TEV protease, and Cas9 was purified by the protocols described previously 3 . Cas9 was stored in "Buffer 5": 20cmM 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES) at pH 7.5, 150 mM KCl, 10% glycerol, 1 mM tris(2-chloroethyl) phosphate (TCEP) and stored at −80 °C. For in vivo experiments, Cas9 was buffer exchanged into "Buffer#1" (25 mM Na phosphate pH 7.25, 300 mM NaCl, 200 mM trehalose) before size exclusion column chromatography and stored at −80 °C. Cas9 protein endotoxin levels were measured using Pierce LAL Chromogenic Endotoxin Quantification Kit Cat. # 88282.
sgRNA target site prediction. sgRNA target sequences were selected using the website http://crispr.mit.edu 27 .
In vitro T7 transcription of sgRNA. The DNA template encoding: T7 promoter, a 20-nt target sequence and an optimized sgRNA scaffold 28 was assembled from synthetic oligonucleotides (Integrated DNA Technologies, San Diego, CA) by overlapping PCR. Target sequences are: sgRNA-tdTom aka sgRNA298 (targets STOP cassette in tdTomato locus), 5′-AAGTAAAACCTCTACAAATG-3′, sgRNA-non-targeting aka sgRNA339 (targets Gal4 sequence that is not present in mouse genome), 5′-AACGACTAGTTAGGCGTGTA-3′, sgRNA-NT3 (targets EGFP gene) 5′-GGTGGTGCAGATGAACTTCA-3′. Briefly, for the sgRNA-tdTom template, the PCR reaction contains 20 nM premix of BS298 (5′-TAA TAC GAC TCA CTA TAG AAG TAA AAC CTC TAC AAA TGG TTT AAG AGC TAT GCT GGA AAC AGC ATA GCA AGT TTA AAT AAG G-3′) and BS6 (5′-AAA AAA AGC ACC GAC TCG GTG CCA CTT TTT CAA GTT GAT AAC GGA CTA GCC TTA TTT AAA CTT GCT ATG CTG TTT CCA GC-3′), 1 µM premix of T25_long (5′-GAA ATT AAT ACG ACT CAC TAT AG-3′) and BS7 (5′-AAA AAA AGC ACC GAC TCG GTG C-3′), 200 µM dNTP and Phusion Polymerase (NEB, Ipswich, MA) according to the manufacturer's protocol. The thermocycler setting consisted of 40 cycles of 95 °C for 10 s, 59 °C for 10 s and 72 °C for 10 s. The PCR product was extracted once with phenol:chloroform:isoamyl alcohol and then once with chloroform, before isopropanol precipitation overnight at −20 °C. The DNA pellet was washed three times with 70% ethanol, air-dried and resuspended in elution buffer.
A 400-µl T7 in vitro transcription reaction consisted of 50 mM Tris-HCl (pH 8), 30 mM MgCl 2 , 0.01% Triton X-100, 2 mM spermidine, 20 mM fresh dithiothreitol, 5 mM of each ribonucleotide triphosphate, 100 µg/ml T7 Polymerase and 1 µM DNA template. The reaction was incubated at 37 °C for 4 h-to-overnight, and 5 units of RNase-free DNaseI (Promega, Madison, WI) was added to digest the DNA template 37 °C for 1 h. The reaction was quenched with 2×STOP solution (95% deionized formamide, 0.05% bromophenol blue and 20 mM EDTA) at 60 °C for 5 min. The RNA was purified by electrophoresis in 10% polyacrylamide gels containing 6 M urea. The RNA band was excised from the gel, crushed in a 15-ml tube, and eluted with five volumes of 300 mM sodium acetate (pH 5) overnight at 4 °C. The supernatant was filtered through a 0.2-µm filter to remove acrylamide fragments. 2.5 equivalents of ethanol was added and the RNA precipitated overnight at −20 °C. The RNA pellet was collected by centrifugation, washed three times with 70% ethanol, and briefly air-dried or vacuum-dried. To refold the sgRNA, the RNA pellet was re-dissolved in dPBS-Ca,-Mg. The sgRNA was heated to 70 °C for 5 min and cooled to room temperature for 5 min. MgCl 2 was added to a final concentration of 1 mM. The sgRNA was again heated to 50 °C for 5 min, cooled to room temperature for 5 min and kept on ice. The sgRNA concentration was determined by OD 260nm using Nanodrop (Thermo Fisher Scientific, Waltham, MA). The sgRNA was stored at −80 °C. Cas9 RNP assembly. Cas9 RNP either was prepared immediately before experiments or prepared and snap-frozen in liquid nitrogen and stored at −80 °C for later use. We did not measure any loss in activity upon freeze-thawing Cas9 RNP complexes. To prepare the Cas9 RNP complexes, we incubated Cas9 protein with sgRNA at 1:1.2 molar ratio. Briefly, we added sgRNA to Buffer#1 (25 mM NaPi, 150 mM NaCl, 200 mM trehalose, 1 mM MgCl 2 ), then added the Cas9 to the sgRNA, slowly with swirling, and incubated at 37 °C for 10 min to form RNP complexes. RNP complexes were filtered before use through a 0.22-µm Costar 8160 Filter pre-wet with 200 µl Buffer#1. If needed, the RNP sample was concentrated with a 0.5 ml Millipore Ultra 100-Kd cutoff filter, part # UFC510096, until the desired volume was obtained. Animals. Mice were maintained on a 12-h light-dark cycle with ad libitum access to food and water. All animals were group-housed and experiments were conducted in strict adherence to the Swiss federal ordinance on animal protection and welfare as well as according to the rules of the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC), and with the explicit approval of the local veterinary authorities. Animals at University of California, Berkeley were maintained on a 12-h light-dark cycle with ad libitum access to food and water. All animals were group-housed and experiments were conducted in strict adherence to the University of California, Berkeley's Animal Care and Use Committee (ACUC) ethical regulations. No randomization was used to allocate animals to experimental groups.
Stereotaxic infusion of Cas9
RNPs. 0×NLS-Cas9-2×NLS and 4×NLS-Cas9-2×NLS RNPs were prepared and shipped by Brett Staahl, UC Berkeley to Roche Pharmaceuticals Basel, Switzerland. 15-to 20-week-old male Ai14 tdTomato mice (which lack the NeoR cassette present in Ai9 tdTomato mice but are otherwise identical) 17 were anesthetized using injectable anesthesia (fentanyl 0.05 mg/kg + medetomidine 0.5 mg/kg + midazolam 5 mg/kg; s.c.). The anesthetized mouse was then aligned on an Angle two stereotactic frame (Leica, Germany) and craniotomies were performed with minimal damage to brain tissue. All stereotaxic coordinates are relative to bregma. Mouse stereotaxic surgery targets: striatum (+0.74 mm anterioposterior, ± 1.74 mm mediolateral, −3.37 mm dorsoventral), hippocampus (−1.94 mm anterioposterior, ± 1.12 mm mediolateral, −1.75 mm dorsoventral), cortex V1 (−3.28 mm anterioposterior, ± 2.4 mm mediolateral, −1.25 mm dorsoventral), cortex S1 (+1.94 mm anterioposterior, ± 2.37 mm mediolateral, −2.00 mm dorsoventral). Cas9 RNPs were infused (0.5 µl/side) using a Neuros 75 5 µL syringe (Hamilton). After infusion, the injector was left at the injection site for 5 min and then slowly withdrawn. After the injections, the operation field was cleaned with sterile 0.9% NaCl and closed with suture (Faden Monocryl Plus 5-0, Aichele Medico) and surgical glue (3M Vetbond Tissue Adhesive). The mouse was kept warm at 37 °C during the surgical procedure and also post-surgery. To avoid drying of the eyes during surgery, an ointment was applied outside of the eyes of the mouse. The mice were left undisturbed for 12 d before cellular analysis. Sample size was chosen based on expected effect size. No randomization was applied while allocating animals to groups.
Immunofluorescence analysis. For immunofluorescence analysis, mice were perfused with 4% paraformaldehyde and post-fixed overnight. Brains were sectioned (coronal plane sections) on a vibratome and 50-µm thick sections were used for antibody labeling. Sections were first treated with blocking solution (0.3% Triton X-100, 10% goat serum in 1× PBS) and incubated with the primary antibody (in blocking solution) overnight at 4 °C. Sections were washed with 1× PBS and incubated in the secondary antibody at room temperature for 3 h. Finally, sections were washed three times in 1× PBS, stained with the DNA binding fluorescence probe DAPI (1 µg/ml, Roche Life Science, Switzerland) and mounted on glass slides in a Prolong gold anti-fade medium (Thermo Fischer, USA).
In vivo tdTomato reporter. For tdTomato reporter analysis, 12-to 14-d post-injection mice were perfused with 4% paraformaldehyde and brains were post-fixed overnight. Brains were sectioned (coronal plane sections) on a vibratome and 50-µm thick sections were DAPI counterstained and endogenous tdTomato + cells counted.
Primary antibodies (Supplementary Table 3 ) used were polyclonal rabbit anti-IBA1 (1:100, Wako, #019-19741), polyclonal rabbit anti-S100β (1:1,000; Abcam,# ab41548), monoclonal rabbit anti-DARPP32 (1:100; Cell Signaling Technologies,# 2306), monoclonal mouse anti-NeuN (1:500; Millipore, #MAB377), polyclonal chicken anti-GFAP (1:500; Abcam,# ab4674) and monoclonal rat anti-CTIP2 (1:100; clone 25B6, Abcam,# ab18465). Secondary antibodies used were donkey anti-rabbit Alexa Fluor 488 (1:500, Jackson Lab, USA, #711-545-152), and donkey anti-rat Alexa Fluor 488 (1:500, Thermo Fischer, USA, #A-21208 ), donkey anti-chicken Alexa Fluor 488 (1:500; Jackson Labs, Bar Harbor, ME, #703-545-155), donkey anti-mouse Alexa Fluor 488 (1:500; Jackson Labs, Bar Harbor, ME, #715-545-150).
Confocal Imaging. Confocal fluorescent images were acquired using a Leica TCS SP5 (Leica Microsystems) inverted microscope. Image analysis and maximum intensity projections of images acquired along the z axis were done using LAS-AF software.
Cell counting. Images for cell counting were acquired using a Leica TCS SP5 (Leica Microsystems) inverted confocal microscope with 20× dry objective. Image analysis and maximum intensity projections of images acquired along the z axis was done using LAS-AF software. Every sixth section from the dorsal striatum was stained with DAPI and used for cell counting. Quantification of Td-tomato and DAPI double-positive cells was done using ImageJ. The total number of edited cells per brain was quantified by multiplying the number of cells counted with the section periodicity (here it is 6). The experimenter was blinded to treatment condition while performing cell counting.
Quantification of fluorescence intensity. Images for quantification were acquired using a Leica TCS SP5 (Leica Microsystems) inverted microscope with 20× dry objective. All parameters were kept constant to allow comparative measurements between images. To quantify the fluorescence intensity corresponding to microglia (IBA-1 staining) at the injection site, we performed reconstruction of the injection site of the slice by recording at least 140 single optical layers (step size system optimized of 0.18 mm) at a 512-512 pixel resolution. The brightest sample was used to define optimal confocal settings with such settings used for the acquisition of all subsequent z stacks. LAS AF Lite software was used to reconstruct 3D projection of the section. Quantification of the intensity of IBA-1 staining in the striatum was done with ImageJ Software. Data are represented as mean ± s.e.m. (One way ANOVA; P = 0.4496 and F 2,7 = 0.898). n = 3 animals per condition with 2-8 sections analyzed per animal. For each section, fluorescence intensity of the IBA-1-labeled channel for the entire 20× field was measured with image J. The experimenter was blinded to treatment condition while performing quantitation of fluorescence intensity.
RNA extraction from brain tissue slices and quantitative RT-PCR.
Bilateral intrastriatal stereotaxic infusion of sham (buffer only) or 50 pmol 4×NLS-Cas9-2×NLS RNPs with sgRNA-tdTomato in 0.5 µl were performed as described earlier. Mice were perfused with ice-cold PBS at 3 d and 12 d after injection. Brains were harvested and cut into 1-mm sections using a brain slicer matrix around the injection site. The slices were transferred to ice-cold PBS and then onto frozen glass slides. The dorsal injected striatum (1 mm thick × 1-1.25 mm wide × 2 mm long) was cut out and frozen on dry ice. On day3, tdTomato + signal was not yet present so we therefore identified the needle track to excise the RNP-treated tissue in the dorsal striatum. On day 12, tdTomato + signal accumulated in edited cells, and we used the needle track in addition to the tdTomato signal to identify RNP-treated tissue in the dorsal striatum. One milliliter of TRIzol reagent (Invitrogen) was added to 50 or 150 mg tissue for 3-day and 12-day post-treatment samples, respectively, and triturated to dissociate tissue. One microgram of total RNA was treated with DNase I to remove potential contamination of genomic DNA. One microgram of DNase I-treated RNA was reverse-transcribed using a First Strand Synthesis kit (Invitrogen). qRT-PCR analysis was performed using SYBR green master mix on a Applied Biosystems Step One Plus. The relative expression from RNA samples was determined using the 2 −∆∆CT method. Values were normalized to the expression of the PPIA housekeeping gene. Error bars represent s.e.m. n = 3 animals, n = 2 injections per animal for each group. To test the statistical significance of observed gene expression differences, we performed two-tailed unpaired t-tests with equal s.d. Primers are listed in Supplementary Table 2 . Sample size was chosen based on expected effect size. No randomization was applied while allocating animals to groups. The experimenter was blinded to treatment condition while collecting tissue.
NexGen sequence analysis. The genomic region flanking the CRISPR target site was amplified by two-step PCR method using primers listed in Supplementary Figure 2a . First, the genomic DNA from the edited and control samples was isolated and PCR amplified 15 cycles using Kapa Hot start high-fidelity polymerase (Kapa Biosystems, Wilmington, MA) according to the manufacturer's protocol. The resulting amplicons were purified by AMPure beads to remove primers and subjected to five cycles of PCR to attach Illumina P5 adapters as well as unique sample-specific barcodes followed by bead purification. Berkeley Sequencing facility performed the AMPure bead cleanup. Barcoded and purified DNA samples were quantified by Qubit 2.0 Fluorometer (Life Technologies, Carlsbad, CA), size analyzed by BioAnalyzer, quantified by qPCR and pooled in an equimolar ratio. Sequencing libraries were sequenced with the Illumina MiSeq Personal Sequencer (Life Technologies, Carlsbad, CA). Amplicon sequencing data were analyzed with CRISPR-GA 29 . This work used the Vincent J. Coates Genomics Sequencing Laboratory at UC Berkeley. 
